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Snail1 is the founding member of the Snail superfamily of zinc-finger transcription factors, which also includes
Snail2 (Slug) and Snail3 (Smuc). The superfamily is involved in cell differentiation and survival, two processes central
in cancer research. Encoded by the SNAI1 gene located on human chromosome 20q13.2, Snail1 is composed of
264 amino acids and usually acts as a transcriptional repressor. Phosphorylation and nuclear localization of Snail1,
governed by PI3K and Wnt signaling pathways crosstalk, are critical in Snail1’s regulation. Snail1 has a pivotal role in
the regulation of epithelial-mesenchymal transition (EMT), the process by which epithelial cells acquire a migratory,
mesenchymal phenotype, as a result of its repression of E-cadherin. Snail1-induced EMT involves the loss of
E-cadherin and claudins with concomitant upregulation of vimentin and fibronectin, among other biomarkers.
While essential to normal developmental processes such as gastrulation, EMT is associated with metastasis, the
cancer stem cell phenotype, and the regulation of chemo and immune resistance in cancer. Snail1 expression
is a common sign of poor prognosis in metastatic cancer, and tumors with elevated Snail1 expression are
disproportionately difficult to eradicate by current therapeutic treatments. The significance of Snail1 as a prognostic
indicator, its involvement in the regulation of EMT and metastasis, and its roles in both drug and immune resistance
point out that Snail1 is an attractive target for tumor growth inhibition and a target for sensitization to cytotoxic drugs.
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The Snail superfamily of transcription factors includes
Snail1, Slug, and Scratch proteins, all of which share a
SNAG domain and at least four functional zinc fingers
[1]. Snail1 has four zinc fingers, located from amino
acids 154 to 259, whereas Scratch and Slug each have
five [2,3]. The comparison of these zinc-finger sequences
has further subdivided the superfamily into Snail and
Scratch families, with Slug acting as a subfamily within
the Snail grouping. The Snail superfamily has been
implicated in various processes relating to cell differenti-
ation and survival [1].
First characterized in Drosophila melanogaster in 1984,
Snail1 also has well-documented homologs in Xenopus, C.
elegans, mice, chicks, and humans [4,5]. In humans, Snail1* Correspondence: bbonavida@mednet.ucla.edu
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article, unless otherwise stated.is expressed in the kidney, thyroid, adrenal gland, lungs,
placenta, lymph nodes, heart, brain, liver, and skeletal
muscle tissues [6,7]. Snail1 is a C2H2 zinc-finger protein
composed of 264 amino acids, with a molecular weight of
29.1 kDa [7] (Figure 1). The SNAI1 gene, which is 2.0 kb
and contains 3 exons, has been mapped to chromosome
20q.13.2 between markers D20S886 and D20S109 [7]. A
Snail1 retrogene (SNAI1P) exists on human chromo-
some 2 [8].
Epithelial-to-mesenchymal transition (EMT) is the
process by which epithelial cells lose their apical polarity
and adopt a mesenchymal phenotype, thereby, increasing
migratory properties, invasiveness and apoptotic resistance.
The expression of mesenchymal markers, like vimentin
and fibronectin, replaces that of the usual epithelial
markers, including E-cadherin, cytokeratins and Mucin-1
[10]. EMT is fundamental to both normal developmen-
tal processes and metastatic cancer. The induction of
epithelial-to-mesenchymal transition (EMT) is Snail1’sed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this






Important features of Human Snai1:
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Figure 1 Amino acid sequences: human and mouse. This figure provides the human Snail1 amino acid sequence. The second representation
of the sequence has important features such as phosphorylation sites and zinc fingers highlighted in various colors. 1) Purple indicates nuclear
localization signals 2) blue is motif 1 for GSK-3β-mediated phosphorylation 3) green is motif 2 for GSK-3β-mediated phosphorylation 4) yellow is
the PAK1 phosphorylation site and 5) gray denotes the zinc-finger region. In addition, human Snail2 (Slug) and mouse Snail1 amino acid sequences
are shown for comparison to the human Snail1 sequence. Human Slug is 48% identical to human Snail1, and mouse Snail1 is 88% identical to human
Snail1. The sequence alignments were run through BLAST [9].
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formation of the mesoderm and the neural crest [1].
Snail1 knockout in mice is lethal because gastrulation
does not occur [11]. The primary mechanism of Snail1-
induced EMT is the repression of E-cadherin, which
causes reduced cell adhesion and promotes migratory
capacity [12]. The further elucidation of Snail1’s role in
EMT provides a critical insight into the development of
metastatic cancer. In addition, Snail1 has been recently
implicated in the regulation of drug/immune resistance
and the cancer stem cell (CSC) phenotype [13-16].
Regulation of Snail1 expression
Transcriptional regulation
The Notch intracellular domain, LOXL2, NF-κB, HIF-1α,
IKKα, SMAD, HMGA2, Egr-1, PARP-1, STAT3, MTA3,
and Gli1 all interact directly with the Snail1 promoter
to regulate Snail1 at the transcriptional level [17-29].
Hypoxic stress, caused by insufficient oxygen, promptsa transcriptional response mediated by hypoxia-inducible
factors (HIFs) [17]. Notch increases HIF-1α recruitment
to the LOX promoter, and LOXL2 oxidizes K98 and/or
K127 on the Snail1 promoter, leading to a conformational
change in shape [18]. Under hypoxic conditions, HIF-1α
binds to HRE2, contained within -750 to -643 bp of the
Snail1 promoter, and increases Snail1 transcription.
Knockdown of HIF-1α results in the repression of both
Snail1 and EMT [19]. NF-κB also binds to the Snail1
promoter, between -194 and -78 bp, and increases its
transcription [20]. SMAD2 and IKKα bind concurrently
to the Snail1 promoter between -631 and -506 bp,
resulting in Snail1’s upregulation [21]. HMGA2 cooper-
ates in this complex as well, as the binding of HMGA2
to the Snail1 promoter increases SMAD binding [22].
In addition, ILK promotes PARP-1 binding, and STAT3
binds as a final result of an IL-6/JAK/STAT pathway
[23,24]. In mice, a pathway beginning with HB-EGF and
progressing through the MEK/ERK pathway has also
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and Snail1 interact through a positive feedback loop: Shh
and Wnt crosstalk results in the upregulation of both [26].
MTA3, a subunit of the Mi-2/NuRD complex, transcrip-
tionally represses Snail1 in an ER-dependent manner.
Snail1, in turn, binds to the ER promoter to complete the
negative feedback loop [27,28]. In a similar fashion, Egr-1
and Snail1 relate via a negative feedback loop. Egr-1, an-
other zinc-finger transcription factor, binds to the Snail1
promoter at four sites between -450 and -50 bp. This
process necessitates the presence of HGF and is mediated
by the MAPK pathway, and it ultimately results in Snail1
upregulation. Snail1, in turn, represses Egr-1 [29].
YY1 and Snail1 itself are two special instances of tran-
scriptional Snail1 regulation. YY1 binds to the 3’ enhan-
cer, rather than the promoter, and knockdown of YY1
has been shown to decrease Snail1 expression [30]. Fur-
thermore, Snail1 is capable of binding to its own pro-
moter and upregulating itself [31]. Snail1 binds to the E
box region within the Snail ILK Responsive Element
(SIRE); PARP-1 also binds to the SIRE, which is located
between -134 and -69 bp, when induced by ILK [23]
(Figure 2).
Experiments conducted to elucidate the relationship
between p53, a tumor suppressor protein, and Snail1 have
shown that p53 acts via miR-34a, -34b, and -34c to repress
Snail1 at a 3’ untranslated region (UTR). Consequently,
when p53 is repressed, the repression of Snail1 is lifted,
and the expression of Snail1 rises [32].
Translational regulation
Two instances of phosphorylation are crucial to Snail1’s
post-transcriptional regulation. GSK-3β phosphorylates
Snail1 at two consensus motifs in serine-rich regions.
The first phosphorylation, at motif 2 (S107, S111, S115,
S119), results in Snail1’s being exported to the cytoplasm.Figure 2 Regulation at the Snail1 promoter. This figure depicts the regu
represents the base-paired sequence, with -750 to -1 bp shown. The relativ
spatially compared using blocks to represent each regulator’s binding site.
where that particular protein binds the Snail1 promoter.The second instance of phosphorylation (S96, S100, S104)
leads to its ubiquitination by β-Trcp, which recognizes
the destruction motif D95SGxxS100 and ubiquitinates
Lys98, 137, and 146. Consequential proteasomal degrad-
ation follows [33,34]. In conditions that prevent GSK-3β
from phosphorylating Snail1, the F-box E3 ubiquitin
ligase FBXL14 appears to cause proteasomal degradation
by ubiquitinating the same lysine residues as β-Trcp
[35]. P21-activated kinase 1 (PAK1) also phosphorylates
Snail1 at S246 [36]. Phosphorylation determines Snail1’s
subcellular location, as GSK-3β -mediated phosphoryl-
ation induces Snail1’s export to the cytoplasm through
exportins such as chromosome region maintenance 1
(CRM1) [33,37]. By contrast, PAK1 phosphorylation
promotes Snail1’s presence in the nucleus and, therefore,
increases its activity [36]. In the cytoplasm, Snail1 is
quickly degraded; it has a half-life of only twenty-five
minutes [33]. To protect from this degradation, Snail1
has nuclear localization signals (NLS): one monopartite
from amino acids 151-152 and one bipartite overlapping
the SNAG domain between amino acids 8 and 16 [38].
These signals are responsible for the nuclear transport
of Snail1, which in turn is required for proper expres-
sion. β-catenin, Lef-1, and IκB employ similar systems
[38] (Figure 3, Table 1).
TNFα, NF-κB, FGF, Wnt, and microRNA signals also
influence the regulation of GSK-3β-mediated phosphor-
ylation. The TNFα/NF-κB pathway induces CSN2, which
protects Snail1 from degradation by interfering with the
binding of GSK-3β and β-Trcp. Thus, Snail1 is neither
phosphorylated nor ubiquitylated [39]. FGF operates
through the PI3K/Akt pathway to downregulate GSK-3β,
and receptor tyrosine kinase induces EGF suppression of
GSK-3β [34,40]. Wnt can also suppress GSK-3β and,
thus, the phosphorylation of Snail1 [41]. Additionally,
miR-148a causes the phosphorylation of AKT and GSK-latory interactions at the human Snail1 promoter. The central line
e locations of interactions with various transcription factors are then
Each block, with the base pairs involved denoted at the top, shows
Figure 3 Snail1 stability and localization. This figure shows the effects of GSK-3β and PAK1-mediated phosphorylation on Snail1 stability and
subcellular localization. The outer circle represents the cell membrane, and the inner circle represents the nucleus. Nuclear Snail1 is phosphorylated by
GSK-3β at motif 2 and is consequently exported from the nucleus. If Snail1 remains in the cytoplasm, it is ultimately ubiquitinated and degraded. By
contrast, phosphorylation by PAK1 favors the nuclear localization of Snail1, which increases its stability.
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This, in turn, inhibited EMT in hepatocellular carcin-
oma [42].
Phosphorylation of upstream targets also influences the
regulation of Snail1. For example, RANKL, in association
with IκB, activates the NF-κB p65 subunit, and Akt
influences the nuclear localization of NF-κB through its
phosphorylation of IKKα and IκB in turn [43,44]. TGF-β1Table 1 Regulation of Snail1 expression
Direct regulators Interaction location
LOXL2/3 SNAG domain; K98 and K127
NF-κB Promoter: -194 to -78 bp
HIF-1α Promoter: -750 to -643 bp
SMADs Promoter: -631 to -506 bp
IKKα Promoter: -631 to -506 bp (concurrent with SMAD
HMGA2 Promoter: 2 regions within -131 to -92 bp
YY1 3’ Enhancer
Egr-1 Promoter: 4 sites between -450 and -50 bp
PARP-1 Promoter: SIRE
Gli1 There are 4 candidate GLI binding sites




GSK-3β Motif 1 (S96, S100, S104) and Motif 2 (S107, S111, S115,
Snail1 Promoter: E box within SIREinduces the phosphorylation of SMAD2 and SMAD3,
which is necessary for their binding to Snail1 and the con-
sequential upregulation of Snail1’s activities [45]. However,
the cooperation of Ras signals is required for this pathway,
since TGF- β1-mediated induction of Snail1 ceases with
the silencing of Ras [46].
Other mechanisms of regulation contribute to the
expression levels of Snail1, too. The small C-terminalUpstream pathway(s) Reference(s)
Notch/Lox [17]
TNFα, RANKL, PI3K/Akt [20,43,44]
Hypoxic conditions [19]
TGF-β1, Ras [45,46]







IL-6/JAK, HB-EGF/EGFR/MEK/ERK (mice) [24,25]
ER [27,28]
[36]
S119) Wnt, PI3K/Akt, FGF [33,34]
Binds to own promoter [31]
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of both GSK-3β and the affected Snail1 motifs, thereby
stabilizing Snail1 [47]. Additionally, histone deacetylase
inhibitors promote the acetylation, likely of lysines, and
increase Snail1’s nuclear localization by inhibiting ubi-
quitination [48].
Snail1’s targets
The variety of targets regulated by Snail1, detailed below,
show that Snail1’s EMT program is driven by multiple
mechanisms (Table 2). While it directly represses epithe-
lial markers like E-cadherin and claudins, Snail1 also upre-
gulates markers of the mesenchymal phenotype, including
vimentin and fibronectin. Frequently, the expression levels
of Snail1’s targets serve as prognostic indicators. For
example, decreased E-cadherin expression correlates with
lower patient survival rates while overexpression of MMPs
associates with invasiveness. In addition to replacing
epithelial with mesenchymal markers, Snail1 upregulates
co-repressors, as in the case of ZEB-1, to complete its
EMT program.
E-cadherin
E-cadherin is a transmembrane glycoprotein responsible
for calcium-dependent cell-to-cell adhesion [49]. E-
cadherin is a type I cadherin encoded by the gene
CDH1, which is located on human chromosome
16q22.1 [50]. The founding member of the cadherin
superfamily, E-cadherin plays a pivotal role in cadherin-
catenin-cytoskeleton complexes, and it grants anti-
invasive and anti-migratory properties to epithelial cells
[51]. E-cadherin expression naturally decreases during
gastrulation in order to properly form the mesoderm,
and its expression increases once more for kidney or-
ganogenesis [52,53]. The CDH1 promoter contains mul-
tiple E-boxes, and Snail1, Slug, ZEB1, ZEB2, and Twist,
among others, have been shown to directly repress E-Table 2 Gene targets regulated by Snail1
Target Target significance
E-cadherin Epithelial marker, adherens junctions
RKIP Tumor suppressor
PTEN Tumor suppressor
Occludin Epithelial marker, tight junctions
Claudins Epithelial markers, tight junctions
Mucin-1 Epithelial marker
ZEB-1 Assists in induction of EMT
Vimentin Mesenchymal marker
Fibronectin Mesenchymal marker
Cytokeratin 18 Epithelial marker
MMP-2/MMP-9 Mesenchymal markers
LEF-1 Mesenchymal marker, assists in inductioncadherin [54]. Total E-cadherin knockout in mice resulted
in immediate death at implantation [55]. Decreases in E-
cadherin expression correlate with epithelial-mesenchymal
transition, metastasis, and lower patient survival rates [10].
Four Snail1 complexes have been identified as mecha-
nisms of E-cadherin repression. (1) Snail1 interacts with
G9a, which concurrently recruits DNA methyltransfer-
ases (DNMTs) to the E-cadherin promoter. Snail1’s zinc
fingers are thought to interact with the G9a ankyrin
repeats, SET domain, or both. The complex has been
shown to increase H3K9me2 and decrease H3K9 acetyl-
ation [56]. (2) The Snail1-Ajuba-PRMT5 complex pro-
motes the methylation of H4R3. This, too, operates at
the E-cadherin promoter [57]. The demethylation of
H3K4 by Co-REST, CtBP, and HDAC complexes also
factors into the last two mechanisms [58]. (3) Snail1
works in conjunction with Sin3A and HDAC1/2 to dea-
cetylate H3 and H4, which suppress E-cadherin [59]. (4)
In perhaps the most elucidated case, the Snail1 SNAG
domain interacts with the LSD1 AO domain to form a
Snail1-LSD1-CoREST complex. Snail1 residues Pro2,
Arg3, Ser4, Phe5, Arg8, and Lys9 have been shown to be
particularly crucial to this union, since mutants could
not interact with LSD1. Likewise, LSD1 requires func-
tional Asp375 and Glu379, Glu553, Glu555 and Glu556
to cooperate with Snail1. LSD1 inhibitors, histone H3,
and SNAG peptides also hamper the activity of the
complex. The formation of the Snail1-LSD1-CoREST
complex results in the demethylation of H3K4me2 and
consequential suppression of E-cadherin, while also
increasing the stability of each of the components of the
complex [60]. In a proposed second step to this mechan-
ism, Snail1 recruits Suv39H1 to the E-cadherin pro-
moter. Similar to prior cases, the Snail1 SNAG domain
interacts with the Suv39H1 SET domain to suppress E-
cadherin. Knockdown of Suv39H1 restored E-cadherin












of EMT Upregulation [83,125]
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Raf kinase inhibitor protein (RKIP), a member of the
phosphatidylethanolamine-binding protein (PEBP) group,
suppresses metastasis by inhibiting the Raf-MEK-ERK and
NF-κB pathways [62-65]. In prostate, breast, and colorec-
tal cancers, among others, RKIP expression is downregu-
lated [64,66]. Furthermore, elevated RKIP expression is a
positive prognostic indicator for survival [66,67]. Expres-
sion levels of RKIP correlate with those of E-cadherin,
another Snail1 target, as they are both repressed by means
of the E-boxes in their promoters [68].
PTEN
Phosphatase and tensin homolog deleted in chromo-
some 10 (PTEN) dephosphorylates phosphoinositide-
3,4,5-triphosphate (PIP3) and, thus, inhibits the PI3K
pathway [69]. In this way, PTEN functions as a tumor
suppressor. Snail1 binds to the PTEN promoter, which
contains two E-boxes, and represses PTEN [70]. The
specificity of this interaction is emphasized by the fact
that neither Slug nor ZEB1 expression significantly alters
PTEN levels [70]. Snail1’s association with the PTEN
promoter inhibits the binding of p53, which activates
PTEN during apoptosis, and it consequently increases
resistance to gamma radiation-induced apoptosis [70,71].
A positive feedback loop has been established around this
interaction as well, since the repression of PTEN increases
the expression of Akt [72]. Akt, operating through NF-κB,
increases the expression of Snail1 [44]. Through this path-
way, Snail1 may contribute to raising its own expression
levels [70].
Occludin
Occludin, an integral membrane protein crucial to the
integrity of tight junctions, was first identified in 1993.
The transmembrane protein has four hydrophobic do-
mains within its 522 amino acid sequence and a molecu-
lar weight of 65 kDa [73,74]. Though it is considered
similar to connexins in gap junctions, occludin is found
exclusively at tight junctions in epithelial and endothelial
cells [73]. Snail1 functions as a transcriptional repressor
of occludin, just as it does E-cadherin in adherens junc-
tions. By binding to the E-box in the occludin promoter
sequence, Snail1 can completely repress the promoter
activity [75]. Immunoblot analysis and immunocyto-
chemistry confirm the considerable reduction of occlu-
din expression in the presence of Snail1 [13]. This
repression, along with that of E-cadherin and claudins, is
critical to the loss of cell-to-cell adhesion observed in
EMT.
Claudins
The claudin family contains more than twenty members,
all of which are integral proteins spanning the membranefour times. Family members range from 20-27 kDa, but
they all share PDZ binding motifs, which allow them to
interact with ZO-1, ZO-2, and MUPP-1, among others
[76]. Claudins are components of tight junctions, and
claudin-1 binds with occludin [76,77]. The expression of
claudins is frequently low or nonexistent in breast cancer
cell lines, and it shares an inverse relationship with Snail1
expression levels in invasive breast tumors [77].
Specifically, claudin-1, -3, -4, and -7 are all susceptible
to repression by Snail1. The promoter sequence of each
of these proteins contains multiple E-box binding motifs:
claudin-1 has two E-boxes, claudin-3 has six, claudin-4
has 8, and claudin-7 has eight. As such, Snail1 can com-
pletely inhibit their transcription [75]. The destruction
of tight junctions that accompanies the repression of
claudins and occludin leads to epithelial cells’ loss of
apical polarity and increases proliferation [78]. This
mechanism helps drive Snail1-induced EMT.
Mucin-1
Mucin-1, a transmembrane glycoprotein encoded by
MUC1, is an epithelial marker expressed at the apical
surface of epithelial cells in the reproductive tract, di-
gestive tract, lungs, kidney, liver, eyes, and other tissues
[79-81]. Additionally, it is expressed in hematopoietic
and T cells [80]. Mucin-1’s functions include lubrication
and protection from pathogens, and its association with
β-catenin has implicated Mucin-1 in cell signaling [80].
O-linked glycosylation affects the protein significantly,
as the core protein ranges from 120-225 kDa and the
glycosylated form can reach up to 500 kDa [82]. In epithe-
lial tumors, Mucin-1 is upregulated, and disparities in
splice variants and glycosylation become apparent [79,80].
Splice variants differ greatly—the protein can vary from 4-
7 kb [82]. Perhaps most importantly, Mucin-1 also loses
its apical restriction in malignant cases [80].
The 2872 bp promoter facilitates much of Mucin-1’s
regulation, and it notably includes five sites for YY1
binding [79]. Snail1 interacts with the two E-boxes that
begin -84 bp from the start of transcription. Like
E-cadherin, Mucin-1 is an epithelial marker repressed by
Snail1 during the induction of EMT [83].
ZEB-1
ZEB-1, like Snail1, is a zinc-finger transcription factor that
assists in the induction of EMT. Using E-boxes and
co-repressors such as CtBP and BRG1, ZEB-1 represses E-
cadherin and Mucin-1 [83,84]. However, ZEB-1 is at least
ten times less potent a repressor of both E-cadherin and
Mucin-1 than Snail1 [83]. Interference with the inter-
action between ZEB-1 and BRG1 results in the upregula-
tion of E-cadherin and simultaneous downregulation of
vimentin, so an abundance of functional ZEB-1 is associ-
ated with a mesenchymal phenotype [84]. In contrast to
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not prevent development to term and, thus, is not as
critical for gastrulation [83].
The presence of Snail1 increases both RNA and pro-
tein levels of ZEB-1 during EMT. Snail1 expression in
MDCK clones causes a 2.5-fold increase in ZEB-1 pro-
moter activity compared to control cells. The abilities of
Snail1 and ZEB-1 to repress E-cadherin are additive, and
the two transcription factors work together to achieve a
complete EMT [83].
Vimentin
Vimentin is 57 kDa intermediate filament generally
restricted to mesenchymal cells [85]. Vimentin regulation
is a complex interplay of epigenetic and post-translational
modifications in addition to transcriptional regulation. Of
note, the human vimentin promoter contains an NF-κB
binding site as well as a TGF-β1 response element [86,87].
Akt1 protects vimentin from caspase proteolysis via phos-
phorylation of Ser39 [88]. During EMT, epithelial cells,
which normally express keratin intermediate filaments,
begin to express vimentin. Overexpression of vimentin is
evident in breast and prostate cancers, among many other
types, and overexpression generally correlates with inva-
siveness, migration, and poor prognosis [89-91]. Snail1
upregulates vimentin during EMT [54].
Fibronectin
Fibronectin is a glycoprotein involved in cell adhesion,
differentiation, and migration [92,93]. A dimer with two
250 kDa components, fibronectin is greatly affected by
splicing, and at least twenty variants of the human form
have been identified [94]. Fibronectin interacts with
many integrins in addition to heparin, collagen, and fi-
brin [95-99]. Inactivation of fibronectin is lethal in mice
[100]. Snail1 upregulates fibronectin, a mesenchymal
marker indicative of EMT [54].
Cytokeratin 18
Cytokeratins exist in two types, and each cytokeratin
works with a complementary partner to form keratin fil-
aments [101]. Cytokeratin 18 is the first type, acidic, and
interacts with the basic cytokeratin 8 [101]. The cytoker-
atin 18 protein is encoded by the CK18 gene, which is
located on chromosome 12q13. Cytokeratin 18 is an
intermediate filament protein involved in cell structure,
cell signaling, and the cell cycle [101-104]. Cytokeratin
18 serves as an epithelial marker, and it localizes in epi-
thelial organs, such as the kidney, liver, gastrointestinal
tract, and mammary glands [105]. Snail1 represses cyto-
keratin 18 during the induction of EMT [83]. Unlike
other targets, though, cytokeratin 18 expression is not
completely subdued by Snail1’s presence [75].MMP 2/9
Matrix metalloproteinases (MMP) cleave extracellular
matrix substrates and, thereby, alter cell-matrix adhe-
sions [106]. MMP-2 and -9 are a subcategory within the
MMP group because they specifically act on gelatin, col-
lagen, elastin, and fibronectin [107-111]. The genes that
encode MMP-2 and -9 both contain fibronectin type II
domains and are consequently three exons longer than
the other MMP genes [107]. MMP-2 is a 72 kDa protein
while MMP-9 is 92 kDa, and the main difference be-
tween them is the MMP-9’s 54 amino acid hinge region
[107,112]. Additionally, MMP-2 localizes in the nucleus
and MMP-9 in the cytoplasm [113]. Overexpression of
MMP-2 and MMP-9 is frequently associated with inva-
sive, metastatic tumors [114-117].
Snail1’s presence increases the mRNA levels of both
MMP-2 and -9 [118]. One suggested interaction includes
the upregulation of MMP-2 and -9 by Snail1 to trigger
EMT and, then, the coordinated effort of Snail1 and Slug
to sustain EMT by continually stimulating MMP-9 [113].
LEF-1
Lymphoid enhancer-binding factor 1 (LEF-1) is a T-cell
factor commonly detected in tumors [119,120]. The tran-
scription factor represses E-cadherin by forming com-
plexes with β-catenin, which, like Snail1, is degraded as a
result of GSK-3β-mediated phosphorylation [11,121-123].
LEF-1 interacts with Snail1 via Wnt, PI3K and TGF-β1
pathways, and both Snail1 and LEF-1 are necessary for a
complete EMT [124]. LEF-1 is considered a mesenchymal
marker, and Snail1 induces its expression and continues
to upregulate it [82,125].
Snail1 expression in cancer
Snail1 is expressed in many types of cancer. Snail1 over-
expression usually correlates with increased migration,
invasion, and metastasis. An inverse relationship with
E-cadherin is expected, and Snail1 consequently corre-
sponds with poor differentiation as well. Frequently,
more advanced malignancies and poor prognosis also
accompany elevated Snail1 expression (Table 3).
Breast carcinoma
Invasive breast carcinomas, including infiltrating ductal
(IDC) and infiltrating lobular carcinomas (ILC), spread
to surrounding breast tissues, lymph nodes and the
pleural cavity. Assigned histological grades, with three
being the highest, correlate with prognosis [126]. Breast
carcinomas can give rise to malignant pleural effusions,
and typical survival rates at that point are a matter of
months [127].
Snail1 is not present in normal breast epithelium, nor
is it present in ILCs (n = 21). Of 17 patients, Snail1 was
expressed in 47% of IDCs, and its expression correlated
Table 3 Snail1 expression in cancers (listed in alphabetical order)
Type of
Cancer






E-cadherin [130]; low expression
level (only 16% of carcinoma
tissues, n = 120)—Slug and




tumors; 3 year progression free
survival rate with positive Snail
expression only 15% [140]
Snail expression associated
with tumor recurrence; elevated





None in normal breast epithelium;
in 47% of IDCs (n = 17); none in ILCs
(n = 4); expression correlates with lymph
node metastases; not found in cells with
constitutively inactive E-cadherin;
expression opposes E-cadherin [128];
Snail overexpressed; Snail/E-cadherin
ratio significantly higher [129]
Snail expression in IDCs (n = 17):
grade 1—none; grade 2—more
than half; grade 3—most [128]
Potential marker of IDC malignancy
[128]; High expression correlated with
shorter effusion-free, disease-free, and
overall survival; correlated with lymph
node metastases and high histologic




Snail expressed in 94% of samples
(n = 70) and ZEB-1 in 96%; nuclear
expression of both correlates with
advanced FIGO stage and lymph
node metastasis; expression of
Snail correlates with poor
differentiation [153]
High Snail expression associated
with late FIGO stage, lymph node





Inverse correlation with E-cadherin
[130]; markedly high expression
(78% of tested tumors, n = 59) of
Snail; Snail-positive in older age
group than Snail-negative (mean
58.9 vs. 49.8, n = 59) [138]; Snail
expressed in all tested CRC cell lines
(Western blot); expression increased
migration and invasiveness; decreased
E-cadherin; led to CSC-like phenotype
and spindle morphology [139]
Increase in expression over disease
progression: 15/23 stage III vs. 6/6
stage IV [138]; significantly higher
rate of metastasis among Snail-
expressing than Snail-negative [139]
Snail expression indicates high




Snail expression higher in diffuse
than intestinal type [134]; inverse
correlation with E-cadherin; significantly
reduced E-cadherin expression;
Snail expression more comparable
to breast than ovarian
carcinoma [129]
Overexpression associated
with tumor size, depth of invasion,
lymph node metastasis, shortened
survival [135]
Considered independent




Inverse correlation of mRNA and
protein levels with E-cadherin
(E-cadherin in Hep-G2 while Snail in
HuL-1, Changliver, HLE, and HLF cells)
[130]; Snail correlates with invasiveness
and metastasis, Snail overexpression in
23% of cases (n = 47) [131]
Higher Snail expression in higher
grade cases (n = 12) [132]
Risk factor for early recurrence
(n = 47) [131]; Snail correlated
with portal vein invasion, metastasis,
poorer prognosis in recurrence-free
survival [132]
[130-132]
Melanomas High mRNA expression in all tested
melanoma cell lines but not primary
melanocytes; low E-cadherin in presence
of Snail [142]; inverse correlation with
E-cadherin [130]; Snail confers invasive




Low E-cadherin/high Snail expression
cells more invasive; E-cadherin positive
had cuboidal shape and E-cadherin
negative cells were spindle-shaped;




Less expressed than in breast carcinoma
[129]; lower expression in effusions than
primary tumors and solid metastases;
mRNA levels not statistically different
among the three; complete cytoplasmic
localization in effusions [133]
High E-cadherin expression
correlated with disease-free
survival; MMP-2 is considered
a marker of poor prognosis;
Snail associated with distant
metastases [129]
[129,133]
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Table 3 Snail1 expression in cancers (listed in alphabetical order) (Continued)
Pancreatic
carcinoma
Inverse correlation with E-cadherin
[130]; significantly reduced E-cadherin
expression [129]; 78% of tested tissues
(n = 36, ductal adenocarcinoma)
showed Snail expression; Snail higher in
undifferentiated cell lines (MiaPaCa-2 and





Significant loss of E-cadherin and
syndecan 1 in high grades, along
with high Snail; only nuclear
localization in PC3 cell lines [151]
High Snail expression correlates





Snail mRNA found in all cases tested
(n = 20), but E-cadherin mutations
appear to be more important than
Snail expression [144]
[144]
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grades [128]. E-cadherin and Snail1 expression levels
are inversely related, and high expression levels of
Snail1 correlate with shorter effusion-free, disease-
free, and overall survival rates (n = 16) [129]. As such,
Snail1 has prognostic significance as a marker of IDC
malignancy [128].
Hepatocellular carcinoma
Snail1 mRNA and protein levels are inversely correlated
with E-cadherin in hepatocellular carcinoma (HCC)
[130]. Snail1 overexpression, which in one study in-
cluded 23% of cases (n = 47), is associated with portal
vein invasion, metastasis, and poor differentiation. Fur-
thermore, Snail1 expression correlates with a poor prog-
nosis in recurrence-free survival and, thus, is considered
a potential risk factor for early recurrence [131,132].
Ovarian carcinoma
Overall, Snail1 expression is lower in ovarian carcinoma
than in breast carcinoma, though its expression is still as-
sociated with distant metastases [129]. Expression is higher
among primary tumors and metastases than effusions, and
effusions show complete cytoplasmic localization of Snail1
[133]. Snail1 represses E-cadherin and upregulates MMPs,
and E-cadherin expression correlates with disease-free
survival while MMP-2 is considered a marker of poor
prognosis [129].
Gastric carcinoma
E-cadherin expression is drastically reduced in gastric
carcinoma, and Snail1 expression levels once again share
an inverse relationship with E-cadherin expression levels
[129]. Snail1 expression levels are more comparable to
breast than ovarian carcinomas, and Snail1 expression is
still higher in diffuse rather than intestinal varieties of
gastric carcinomas [129,134]. Elevated Snail1 expressionincreases cells’ capacities for migration and invasion.
Overexpression correlates with tumor size, depth of
invasion, and lymph node metastasis. Shortened sur-
vival rates are also directly related to Snail1 overex-
pression, and Snail1 is considered a predictor of poor
prognosis [135].
Oral squamous carcinoma
Oral squamous carcinoma is another case of E-cadherin/
Snail1 expression inversion, and the higher the Snail1
expression, the more invasive the cancer. E-cadherin
positive cells maintain their cuboidal shape while E-
cadherin negative cells turn spindle-shaped. This is a
typical sign of EMT, and it shows Snail1’s repression of
E-cadherin [136].
Pancreatic carcinoma
Pancreatic carcinoma tissues show significantly reduced
E-cadherin levels and relatively high Snail1 expression
[129]. In one study, 78% (n = 36) of ductal adenocarcin-
oma tissues expressed Snail1, and Snail1 expression is
higher in undifferentiated cell lines than in differentiated
ones [137].
Colorectal carcinoma
Colorectal cancer (CRC) begins in gland cells that line
the colon and rectum, and it is one of the most com-
monly newly diagnosed cancers and a leading cause of
cancer-related deaths [138]. Snail1 expression is again
inversely correlated to E-cadherin expression in CRC,
and the expression level of Snail1 is quite high in CRC
(78%, n = 59) [130,139]. Interestingly, the mean age of
the Snail1-positive group was nine years older than the
Snail1-negative group in one study, with a standard devi-
ation of 12.7 years (58.9 years vs. 49.8 years, n = 59)
[139]. In another study, Snail1 expression was detected
by Western blot in all tested CRC lines, and its
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erties. Additionally, Snail1 expression led to a stem-cell
like phenotype and spindle shape, as usually accompan-
ies the loss of E-cadherin [140]. Snail1 expression also
increased with the stage of the tumors, with 15/23 stage
III expressing Snail1 and 6/6 of stage IV. The signifi-
cantly higher rate of metastasis associated with Snail1
expression suggests that Snail1’s presence indicates a
high risk of distant metastases [139,140].
Bladder carcinoma
Though the expression level of Snail1 is lower in bladder
carcinoma than in other types of cancer, its presence still
has a significant impact on the cancer’s progression. In
one study, only 16% of the 120 tested tissues expressed
Snail1, indicating that Slug and Twist, whose expression
levels were 63% and 44% respectively, play larger roles.
However, Snail1 expression increased in node-positive
compared to node-negative tumors, and Snail1’s pres-
ence lowered the three-year progression free survival
rate to only 15% [141]. Since Snail1 expression is closely
linked with tumor recurrence, its elevation is considered
a significant prognostic factor [141,142].
Melanoma
In melanoma, there is increased Snail1 mRNA and low
E-cadherin in the presence of Snail1 expression. By con-
trast, no Snail1 mRNA was detected in primary melano-
cytes [143]. Snail1 expression confers both invasive and
immunosuppressive properties in melanoma [144].
Synovial sarcoma
Saito et al. reported that Snail1 mRNA was found in all
cases tested of synovial sarcoma (n = 20) and E-cadherin
mRNA was detected by RT-PCR in 14/20 cases. This
does not show the same strong inverse correlation that
has come to be expected of Snail1 and E-cadherin. In
this case, mutations of the CDH1 gene, which encodes
E-cadherin, seem to be more influential than the pres-
ence of Snail1 [145].
Prostate cancer
Prostate cancer is the second most commonly diagnosed
cancer in men worldwide, with estimates of over 900,000
new cases per year [146]. A Gleason grade, which
describes the two most important histopathological pat-
terns of that patient’s cancer, accompanies a diagnosis.
The grade ranges from 2-10 with a higher score meaning
less differentiated [147]. Significant losses of E-cadherin
and syndecan 1, two proteins involved in cellular adhe-
sion, have been observed in malignant prostate cancer
[148,149]. Both promoters contain E-boxes, so Snail1
can directly bind and repress them [150,151]. The pres-
ence of E-boxes may explain the inverse correlationbetween E-cadherin/syndecan 1 and Snail1 expression
levels. Poblete et al. found that high Snail1 expression
correlated with a high Gleason grade and increased malig-
nancy. Furthermore, in more malignant cell lines, like
PC3, Snail1 had exclusively nuclear localization. By con-
trast, Snail1 had both cytoplasmic and nuclear localization
in less malignant cell lines [152].
Cervical carcinoma
Cervical cancer is one of the most common malignan-
cies in women worldwide [138]. Chen et al. found Snail1
expressed in 94% of samples (n = 70), and the elevated
expression of Snail1 correlated with late FIGO stage,
lymph node metastasis, and poor differentiation [153].
Snail1 and cancer stem cells
Snail1-induced EMT causes a stem-like phenotype, a
property closely related to metastasis and resistance.
Cancer stem cells (CSCs), or tumor-initiating cells, are
subpopulations within tumors that possess self-renewing
capabilities [154]. In breast tissue, for example, popula-
tions with a CD44high/CD24low phenotype have a higher
tumor-initiating capacity than do their CD44low/CD24high
counterparts within the same tumors [155]. CSCs are also
associated with chemoresistance, relapse, and metastasis
[156].
Mani et al. reported that EMT could induce stem-like
properties in non-cancerous mammary epithelial cells
[14]. The CD44high/CD24low phenotype correlates with
both breast CSCs and normal mammary stem cells, and
both Snail1- and Twist-induced EMTs stimulated this
same phenotype in nontumorigenic human mammary
epithelial cells (HMLEs). These EMTs also increased the
HMLEs’ mammosphere-forming ability thirty-fold, and
the CD44high/CD24low cells are able to produce more
CD44high/CD24low cells in addition to CD44low/CD24high
cells. Furthermore, these CD44high/CD24low cells exhibited
a decrease of E-cadherin expression along with elevated fi-
bronectin, vimentin, Snail1, and Twist, as measured by
RT-PCR [14]. Thus, EMT promotes self-renewal capabil-
ities and the stem-like phenotype.
Given that Snail1 induced EMT and a stem-like
phenotype in human colorectal cancer cells (as mentioned
in “Colorectal Carcinoma,” above), Zhou et al. examined
human pancreatic cancer cells and reached similar con-
clusions [15]. Epithelial BxPC-3 cells were compared
with more morphologically diverse Panc-1 cells, and the
comparison identified Panc-1 cells, which had higher
Snail1 expression and were more poorly differentiated
than BxPC-3 cells, as CSChigh with a larger ALDHhigh
population [15]. Stem cells’ pluripotent capabilities are
maintained in part by the polycomb complex protein
BMI-1 (Bmi-1), homeobox protein Nanog, sex-determining
region Y-box 2 (Sox2), and octamer-binding transcription
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crease in ALDH, Sox-2, Oct-4, and invasive properties. Fol-
lowing Snail1 knockdown, E-cadherin expression increased
as vimentin and ZEB1 expressions both decreased. With-
out Snail1, the Panc-1 cells underwent MET and conse-
quently lost their stem-like phenotype [15].
In a similar study of non-small cell lung cancer, Wang
et al. compared ciplatin-resistant A549 cells with their
A549 counterparts [16]. A549/CDDP cells showed in-
creased expression levels of Nanog, Oct4, and Bmi-1, as
detected by Western blot. RT-PCR also showed increased
CD44 and Sox2. Migratory and invasive capacities were
increased in A549/CDDP cells, as well. Interestingly, only
Snail1 expression was elevated in A549/CDDP cells—Slug,
Twist, and ZEB1 were not influential factors in this com-
parison. Snail1 knockdown again caused a decline in mi-
gration, invasiveness, Bmi-1 expression, Oct-4 expression,
and mammosphere-forming ability. E-cadherin increased
as vimentin decreased, and the cells became more respon-
sive to cisplatin [16]. Since β-catenin had effects on the
system comparable to active Snail1, an antagonist of the
PI3K/Akt pathway was introduced, and this resulted in a
decrease in β-catenin, Snail1, Nanog, migration, invasive-
ness, and mammosphere-forming ability [16]. Thus, the
Akt pathway plays a crucial role in stem-like phenotype in
lung cancer cells.
Poor differentiation, sphere-forming capacity, self-
renewal, and typical markers such as ALDH and CD44,
among other properties, characterize the stem-like pheno-
type [15]. Clearly, Snail1 overexpression is associated with
all of these properties. After Snail1 induces EMT, cells
adopt a mesenchymal morphology, become more inva-
sive, increase migratory capacity, and express a stem-
like phenotype. Knockdown of Snail1 causes the reverse
process, mesenchymal-epithelial transition (MET), which
prompts cells to become less invasive, migratory, and
stem-like, as well as more sensitized to drugs. Thus,
Snail1-induced EMT is a critical link between resist-
ance, metastasis, and stem-like characteristics.
Regulation of EMT, in part, by Snail1
Snail1 drives EMT primarily through the direct repres-
sion of E-cadherin [53]. Other targets that contribute to
Snail1’s EMT program were detailed above (See Section
“Snail1’s Targets”, Table 2). However, other transcription
factors, notably, TGF-β, RANKL, Notch1, and Cox-2,
Notch1 are crucial to the EMT phenotype as well.
Zhu et al. have examined the relationship between the
expression of the Response Gene to Complement-32
(RGC-32) and TGF-β-mediated EMT [160]. RGC-32 is
over-expressed in many cancers and correlates with the
lower level of expression of E-cadherin in pancreatic
cancer. Stimulation of cells with TGF-β was associated
with the upregulation of RGC-32 and EMT. Noteworthy,the findings that RGC-32 mediated TGF-beta-induced
EMT and cell migration was corroborated with the use
of RGC-32 siRNA. The authors extrapolated that RGC-
32 regulates Snail1 expression and EMT.
Snail1 is a target of NF-κB activity and its expression and
role in EMT are well recognized. Since NF-κB is activated
by many signals, clearly, such signals will also regulate
Snail1 among other target gene products. Tsubaki et al.
have reported that various solid tumors express the Recep-
tor Activator of Nuclear Factor-κB (RANK) and it is
activated by RANK-ligand resulting in the promotion of
tumor cell growth, migration, metastasis, and anchorage
independence in breast cancer cells [42]. In addition, they
reported that RANKL induces EMT by activating NF-κB
and enhances the expression of Snail1, Twist, vimentin,
and N-cadherin and decreases the expression of E-
cadherin. Inhibitors of NF-κB are shown to inhibit
RANKL-mediated EMT, cell migration, and invasion.
Huang et al. investigated the expression level of Notch1
in lung adenocarcinoma and its relationship to metastasis
[161]. They found that lung tumors express low levels of
Notch1 and were associated with advanced clinical stage
and lymph node metastasis. In contrast, patients with posi-
tive Notch1 expression had the prolonged progression of
overall survival. Thus, Notch1 expression regulates nega-
tively the EMT phenotype. Dysregulation of the Notch sig-
naling pathway plays an important role in the pathogenesis
of many cancers. Notch1 is one receptor of the Notch
signaling pathway. Notch1 is involved in the regulation of
tumor cell growth, proliferation, apoptosis, metastasis, and
chemoradioresistance. Notch1 protects Snail1 from deg-
radation by preventing GSK-3β-mediated phosphorylation
via LOXL2 oxidation, as detailed above [18].
The relationship between the expression of cyclooxegnase-
2 (Cox-2) and the downregulation of E-cadherin and its
relationship to the EMT phenotype was reported by
Fujii et al. [162]. These investigators examined Head
and Neck Squamous Cell Carcinoma (HNSCC) cells
and treated the cells with Cox-2 inhibitors (Celecoxib,
NS-398 and SC-791) and examined EMT-associated
gene products by quantitative real-time PCR and West-
ern blot. The findings demonstrated that the inhibitors
upregulated E-cadherin and inhibited its transcriptional
repressors such as Snail1. The investigators suggested
that the administration of Cox-2 inhibitors may suppress
EMTand metastasis via re-expression of E-cadherin.
Snail1 regulates chemo and immune resistance
Reducing Snail1 expression has proven Snail1’s involve-
ment in tumor resistance to many chemotherapeutic
drugs and immunotherapies. In melanoma, Snail1 knock-
down, as a result of siRNA treatment, stops both tumor
metastasis and immunosuppression. Tumor-specific T cell
responses also intensify as a result of this knockdown
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adriamycin-resistant melanoma cells, and Snail1 reduction
leads to cisplatin sensitization in lung adenocarcinoma,
head and neck squamous, and ovarian cancers [13,163-
165]. Additionally, Snail1 has been implicated in resistance
to radiation and paclitaxel in ovarian cancer cell lines as
well as protection against 5-fluorouracil and gemcitabine
in Panc-1 cells [166,167].
Snail1 also factors into resistance because of its
involvement in survival pathways. Snail1’s activation of
MAPK and PI3K survival pathways leads to resistance to
serum depletion and TNF-α [168]. The repression of
NF-κB and therefore Snail1, its downstream target, sensi-
tizes tumor cells to cisplatin and TNF-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis. Treatments
with nitric oxide, the proteasome inhibitor NPI-0052, and
rituximab all achieve this repression and consequential
resistance reversal. These treatments have proven effective
in prostate cancers and B-Non-Hodgkin’s Lymphoma,
respectively [168-171].
Akalay et al. reported that the overexpression of Snail1
in breast cancer cell lines resulted in resistance to CTL-
mediated killing and was associated with the EMT
phenotype. The resistant cells exhibited amodulation of
the formation of the immunologic synapse with CTLs
along with the induction of autophagy in the target cells.
The findings also showed that the inhibition of autophagy
by targeting Beclin-1 sensitized the EMT cells to CTL kill-
ing. Hence, tumor cells’ resistance to CTL is mediated by
EMT-induced activation of autophagy-dependent mecha-
nisms [172,173].Chemical inhibitors targeting Snail1
Few chemical inhibitors target Snail1 directly. However,
Snail1-induced EMT has been successfully abrogated by
a select few chemical inhibitors. LSD and HDAC inhibi-
tors, as well as drugs targeting Snail1/p53 and Snail1/
E-cadherin interactions, have shown efficacy (Figure 4,
Table 4). Their interactions are detailed below.
K-Ras-induced Snail1 represses p53, a tumor suppres-
sor encoded by the TP53 gene, by binding directly and
inducing exocytosis [174]. Lee et al. have developed two
chemical inhibitors, GN25 and GN29, which prevent
this binding and thereby protect p53 and its downstream
targets, like p21, from Snail1 [175]. In K-Ras-mutated
A549, HCT116, and MKN45 cell lines, both inhibitors
were shown to be effective, though GN25 was more so.
GN25 and GN29 also inhibited proliferation with more
success than did Nutlin-3, which interferes with p53/
MDM2 binding. In vivo studies indicated that the pres-
ence of GN25 reduced tumor progression as well as in-
creased tumor regression. While this mechanism did not
have cytotoxic effects on normal cells in this study, it doeshave some limitations. GN25 only activated wild-type p53
and was not effective in normal fibroblasts and Panc-1
cells. Additionally, this mechanism is effective exclu-
sively in K-Ras-activated cancer cells, not N-Ras/Myc-
transformed cells [175].
Harney et al. reported that Co(III)-Ebox, a Co(III)
Schiff base complex, interferes with Snail1/E-cadherin
binding and thereby inhibits Snail’s repression of the E-
cadherin promoter in breast cancer cells [176]. Both the
zinc finger region and ability to bind to E-box sequences
are critical to this mechanism. With the introduction of
Co(III)-Ebox, an increase in E-cadherin gene activity was
observed. A 15 nM dose of Co(III)-Ebox achieved max-
imum results. While Co(III)-Ebox decreased DNA bind-
ing, it did not have an effect on Snail1 protein levels in
this study [176].
Javaid et al. showed that LSD1, LSD2, and HDAC
inhibitors are also effective in countering Snail1-induced
EMT [177]. In breast epithelial cells, the LSD1/LSD2
inhibitor Tranylcypromine (TCP) and the HDAC class I
and II inhibitor Trichostatin A (TSA) individually de-
creased Snail1’s effects on epithelial and mesenchymal
markers. TSA almost completely reversed EMT markers’
expressions, indicating that HDAC inhibitors can ob-
struct EMT maintenance in addition to induction. Treat-
ment with both TCP and TSA simultaneously inhibited
Snail1-induced EMT, as well as TGF-β-induced EMT.
The LSD1 inhibitor Pargyline and the HDAC1, HDAC2,
HDAC3, and HDAC6 inhibitor LBH589 were also
successful in inhibiting Snail1-induced EMT [177].
Furthermore, Shah et al. found that the HDAC inhibi-
tor entinostat (ENT) reverses Snail1-induced EMT in
breast cancer cells [178]. Treating MDA-MB-231 and
Hs578T cells with ENT caused an increase in E-cadherin
transcription with a concomitant reduction of N-cadherin
mRNA. ChIP showed increased E-cadherin promoter ac-
tivity as well as a reduction in the association of Twist and
Snail1. ENT reduced the percentage of CD44high/CD24low
cells in time and dose dependent manners, and Western
blot showed downregulation of Twist and Snail1. Con-
sequently, N-cadherin was reduced, cytokeratin 18 was
upregulated, and vimentin was downregulated. Phos-
phorylation of vimentin increased, and remodeling
resulted in a more rounded cell shape. As such, cell
morphology became increasingly epithelial and cell migra-
tion decreased. ENT thus reverses EMT in triple-negative
breast cancer cells, limiting invasive and metastatic poten-
tial [178].
Many chemical inhibitors have been developed to tar-
get gene products upstream of Snail1. MEK is an attract-
ive target for selective inhibition because of its allosteric
binding site, which allows for noncompetitive inhibition,
and because all tumors dependent on MAPK signaling
are potentially vulnerable to MEK inhibitors [179]. For
A. Synthesis and structures of GN25 and 
GN29
B. Structure of Co(III)-Ebox 
C. Structure of LSD1/LSD2 inhibitor Tranylcypromine 
D. Structure of HDAC inhibitor 
Trichostatin A 
E. Structure of Pargyline
F. Structure of LBH589 
(Panobinostat) 
G. Structure of the HDAC 
inhibitor Entinostat
Figure 4 Structures of chemical inhibitors targeting Snail1. A) GN 25 and GN 29 [175] B) Co(III)-Ebox [176] C) Tranylcypromine [183]
D) Trichostatin A [184] E) Pargyline [185] F) LBH589 [186] and G) Entinostat [187].
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Table 4 Chemical inhibitors that target Snail1-induced EMT
Name Inhibits Effect Known limitations Reference
GN25, GN29 Snail/p53 interaction Reduced proliferation, tumor progression;
increased tumor regression
Only effective in K-Ras activated
cancer cells and on wild-type p53
[174,175]
Co(III)-Ebox Snail/E-cadherin interaction Increased E-cadherin expression [176]
Tranylcypromine LSD1/LSD2 Decreased Snail’s effects on EMT markers [177]
Trichostatin A HDAC1/HDAC2 Reversed EMT marker expression [177]
Pargyline LSD1 Abrogated Snail-induced EMT [177]
LBH589 HDAC Abrogated Snail-induced EMT [177]
Entinostat HDAC Increased E-cadherin and cytokeratin 18 expression,




Kaufhold and Bonavida Journal of Experimental & Clinical Cancer Research 2014, 33:62 Page 14 of 19
http://www.jeccr.com/content/33/1/62example, trametinib, a MEK inhibitor, showed higher
progression-free and overall survival at six months in
phase III trials and was approved by the FDA in May
2013. Selumetinib, which is in phase II trials, has also
shown increased PFS and OS [180]. Since PI3K and
mTOR have similar catalytic sites, ATP-competitive
compounds that target both have been developed in an
attempt to increase efficacy. Pre-clinical studies show
that dual PI3K/mTOR inhibitors reduce proliferation
and induce apoptosis [181].
Ongoing clinical trials targeting Snail1
Very few ongoing clinical trials relate to Snail1’s role in
cancer [182]. In one study, “Polyethylene Glycol 3350 in
preventing cancer in patients at risk of colorectal cancer”
(NCT00828984), Snail1’s presence will be quantified by
immunohistochemistry and RT-PCR. However, Snail1’s
role is secondary to EGFR, the true target. The phase II
study, which is being conducted by the National Cancer
Institute, is listed as recruiting and was last verified in
October 2013 [182].
The use of Snail1 as a search term generates a list in-
cluding collections of tissue samples to study resistance
(NCT00880503, NCT00026663) as well as stem cell trans-
plants (NCT01239368, NCT00923845, NCT00074490),
but none of these mentions Snail1 specifically in their
research descriptions [182]. A phase I HDAC inhibitor
study, “A phase I study of belinostat in combination with
cisplatin and etoposide in adults with small cell lung car-
cinoma and other advanced cancers” (NCT00926640),
also appears in this list, though it does not cite Snail1 as a
target either. The NCI is conducting this study, which was
listed as recruiting in its most recent update on March 14,
2014 [182].
Conclusions and future directions
Snail1, the founding member of the Snail superfamily, is
a zinc-finger transcriptional repressor critical to many
biological processes. The repression of epithelial markerslike E-cadherin, claudins, and mucin-1, in addition to
the upregulation of vimentin, fibronectin, and MMPs,
facilitates the loss of cell adhesion. Thus, Snail1 confers
migratory and invasive properties on epithelial cells. This
progression of changing from epithelial cells to a mesen-
chymal phenotype, known as EMT, is crucial to processes
such as gastrulation. Snail1 has also been implicated in
cell differentiation and survival.
Snail1 is widely expressed in various cancers, and over-
expression is frequently associated with migration, inva-
sion and metastasis. Also correlated with recurrence and
a lack of differentiation, Snail1 serves as a poor prognos-
tic indicator in hepatocellular carcinomas, gastric carcin-
omas, and bladder carcinomas, among others. Therefore,
combatting Snail1’s presence could prove pivotal in
improving cancer prognoses.
To that end, the development of chemical inhibitors
for both Snail1 and targets further upstream has begun
[183-187]. PI3K, MEK, and mTOR inhibitors are making
great strides, and combinations of these prove even
more effective. However, many more Snail1-targeting
therapies are possible. There are few Snail1-specific chem-
ical inhibitors, and even fewer in clinical trials. Snail1 is
ineffective when its nuclear localization is compromised.
As such, more can be done to facilitate the phosphoryl-
ation and consequential degradation of Snail1 by GSK-3β
and proteasomes, respectively. MicroRNA and epigenetic
modifications are continually expanding areas of research.
Snail1’s roles in metastasis, recurrence, and resistance
make it a novel and pleiotropic target in cancer, and im-
proving our understanding of Snail1 could thus provide
new ways of approaching the treatment of metastatic
cancer.
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homolog; MEK: MAPK kinase; MTA3: Metastasis-associated protein 3;
MUPP-1: Multi-PDZ domain protein 1; NF-κB: Nuclear factor kappa-B;
NuRD: Nucleosome remodeling deacetylase; Oct-4: Octamer-binding
transcription factor 4; PAK1: p21-activated kinase 1; PARP-1: Poly(ADP-ribose)
polymerase-1; PI3K: Phosphatidylinositol 3-kinase; PRMT5: Protein arginine
methyltransferase 5; RANKL: Receptor activator of nuclear factor kappa-B ligand;
STAT3: Signal transducer and activator of transcription 3; Sox-2: Sex determining
region Y-box 2; TGF-β1: Transforming growth factor beta 1; TNFα: Tumor
necrosis factor alpha; TRAIL: TNF-related apoptosis-inducing ligand; YY1: Yin
Yang 1; ZEB1/2: Zinc finger E-box-binding homeobox 1/2; ZO-1/2: Zonula
occludens protein 1/2.
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